Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2026 · third_quarter · Q3
Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication
Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Oppose overly restrictive proposals that would provide coverage for breakthrough medical devices Support robust funding for the NIH in FY2027 appropriations
Source: Senate LDA
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Oppose Most Favored Nation style drug pricing policies Support Investigation-al New Drug Pilot Program to accelerate clinical trial timelines Support bipartisan effort to address health care workforce shortage Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit
Support robust domestic supply chain development and manufacturing ecosystem
Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support full funding across HHS departments
Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR)
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2026 · second_quarter · Q2
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support robust funding for the NIH in FY2027 appropriations
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Support full funding across HHS departments
Support robust domestic supply chain development and manufacturing ecosystem
Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment
Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR)
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2026 · first_quarter · Q1
Support robust domestic supply chain development and manufacturing ecosystem
Support full funding across HHS departments
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment
Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR)
CALIFORNIA LIFE SCIENCES via CALIFORNIA LIFE SCIENCES
2025 · fourth_quarter · Q4
Support full funding across HHS departments
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment
Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication
Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit
Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
Oppose "march-in" rights and "compulsory licensing" proposals Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
Support robust domestic supply chain development and manufacturing ecosystem
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR)